Literature DB >> 31350554

Breaking avelumab resistance with combined ipilimumab and nivolumab in metastatic Merkel cell carcinoma?

V Glutsch1, H Kneitz1, M Goebeler1, A Gesierich1, B Schilling2.   

Abstract

Entities:  

Year:  2019        PMID： 31350554     DOI： 10.1093/annonc/mdz230

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

Review 1.  Current concepts and approaches to merkel cell carcinoma.

Authors:  Marianna Babadzhanov; Nicole Doudican; Reason Wilken; Mary Stevenson; Anna Pavlick; John Carucci
Journal:  Arch Dermatol Res       Date:  2020-07-14       Impact factor: 3.017

2.  Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma.

Authors:  Valerie Glutsch; Hermann Kneitz; Anja Gesierich; Matthias Goebeler; Sebastian Haferkamp; Jürgen C Becker; Selma Ugurel; Bastian Schilling
Journal:  Cancer Immunol Immunother       Date:  2021-01-13       Impact factor: 6.968

Review 3.  Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence.

Authors:  Connor J Stonesifer; A Reza Djavid; Joseph M Grimes; Alexandra E Khaleel; Yssra S Soliman; Amanda Maisel-Campbell; Tiffany J Garcia-Saleem; Larisa J Geskin; Richard D Carvajal
Journal:  Front Oncol       Date:  2021-12-20       Impact factor: 6.244

4.  Long-term response to avelumab and management of oligoprogression in Merkel cell carcinoma: A case report.

Authors:  Inês Leão; Joana Marinho; Telma Costa
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.